跳转至内容
Merck

K0600000

酮康唑

European Pharmacopoeia (EP) Reference Standard

别名:

(±)--1-乙酰基-4-(4-[(2-[2,4-二氯苯基]-2-[1H-咪唑-1-基甲基]-1,3-二氧戊环-4-基)-甲氧基]苯基)哌嗪

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C26H28Cl2N4O4
CAS号:
分子量:
531.43
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

ketoconazole

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

CC(=O)N1CCN(CC1)c2ccc(OC[C@H]3CO[C@@](Cn4ccnc4)(O3)c5ccc(Cl)cc5Cl)cc2

InChI

1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m0/s1

InChI 密鑰

XMAYWYJOQHXEEK-OZXSUGGESA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

CYP3A4抑制剂

生化/生理作用

抗真菌剂

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

訊號詞

Danger

危險分類

Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 1B - STOT RE 2

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Masato Ohbuchi et al.
Antimicrobial agents and chemotherapy, 57(3), 1332-1338 (2013-01-01)
The antifungal efficacy of voriconazole (VRC) differs among host species, with potent efficacy in humans but less in rodents. We investigated the possible involvement of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) in the species-specific efficacy of VRC
B Halama et al.
Clinical pharmacology and therapeutics, 93(6), 564-571 (2013-03-21)
The objective of the study was to establish an in vivo method for assessing cytochrome P450 3A (CYP3A) activity using therapeutically inert nanogram doses of midazolam. We administered four escalating single doses of oral midazolam (0.0001-3 mg) to 12 healthy participants
Hao Li et al.
The Journal of biological chemistry, 288(19), 13655-13668 (2013-03-26)
Ketoconazole binds to and antagonizes pregnane X receptor (PXR) activation. Yeast high throughput screens of PXR mutants define a unique region for ketoconazole binding. Ketoconazole genetically interacts with specific PXR surface residues. A yeast-based genetic method to discover novel nuclear
K-H Shin et al.
Clinical pharmacology and therapeutics, 94(5), 601-609 (2013-06-21)
This study aimed to evaluate endogenous metabolic markers of hepatic cytochrome P450 (CYP)3A activity in healthy subjects using a metabolomics approach. Twenty-four subjects received the following medication during the following three study periods: 1 mg of i.v. midazolam alone (control
Jan Faergemann et al.
Expert opinion on pharmacotherapy, 8(9), 1365-1371 (2007-06-15)
Seborrhoeic dermatitis (SD) is a chronic, inflammatory skin disorder, affecting areas of the head and body where sebaceous glands are most prominent and active. The disorder commonly affects hair-bearing areas of the head, including the scalp. Involvement on the face

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门